[
  {
    "ts": "2026-01-08T13:57:00+00:00",
    "headline": "Can These Dividend Stocks Beat the Market Again in 2026?",
    "summary": "There is an even more important question to address.",
    "url": "https://www.fool.com/investing/2026/01/08/can-these-dividend-stocks-beat-the-market-again-in/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "95cb2990-d1dd-3728-8d60-203cddd3af10",
      "content": {
        "id": "95cb2990-d1dd-3728-8d60-203cddd3af10",
        "contentType": "STORY",
        "title": "Can These Dividend Stocks Beat the Market Again in 2026?",
        "description": "",
        "summary": "There is an even more important question to address.",
        "pubDate": "2026-01-08T13:57:00Z",
        "displayTime": "2026-01-08T13:57:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/94518b5e1f9ba37d5ea4bb854cf5a5c0",
          "originalWidth": 1400,
          "originalHeight": 828,
          "caption": "Pharmacist talking to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Vlbmit7_4h3VuCcLNkdoNA--~B/aD04Mjg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/94518b5e1f9ba37d5ea4bb854cf5a5c0.cf.webp",
              "width": 1400,
              "height": 828,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2rBZuZlQTdPxKkdzjG_RFA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/94518b5e1f9ba37d5ea4bb854cf5a5c0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/08/can-these-dividend-stocks-beat-the-market-again-in/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dividend-stocks-beat-market-again-135700367.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "CVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T16:14:18+00:00",
    "headline": "Should Amgen’s (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors?",
    "summary": "In early January 2026, DISCO Pharmaceuticals announced it had granted Amgen exclusive global rights to develop and commercialize cancer therapies based on a cell-surface target identified by DISCO’s proteomics and protein community mapping platform, with DISCO eligible for up to US$618 million in potential payments plus royalties. The deal gives Amgen access to a differentiated surfaceome-targeting engine that can inform bispecific antibody-drug conjugates and T‑cell engagers, potentially...",
    "url": "https://finance.yahoo.com/news/amgen-amgn-exclusive-disco-oncology-161418777.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "cffe828b-99e4-34cb-a70d-ed42e0b00435",
      "content": {
        "id": "cffe828b-99e4-34cb-a70d-ed42e0b00435",
        "contentType": "STORY",
        "title": "Should Amgen’s (AMGN) Exclusive DISCO Oncology Deal Require Action From Investors?",
        "description": "",
        "summary": "In early January 2026, DISCO Pharmaceuticals announced it had granted Amgen exclusive global rights to develop and commercialize cancer therapies based on a cell-surface target identified by DISCO’s proteomics and protein community mapping platform, with DISCO eligible for up to US$618 million in potential payments plus royalties. The deal gives Amgen access to a differentiated surfaceome-targeting engine that can inform bispecific antibody-drug conjugates and T‑cell engagers, potentially...",
        "pubDate": "2026-01-08T16:14:18Z",
        "displayTime": "2026-01-08T16:14:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-exclusive-disco-oncology-161418777.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-exclusive-disco-oncology-161418777.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T17:11:00+00:00",
    "headline": "Alveus launches with $160M to advance MariTide-like obesity drug",
    "summary": "The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as well as an amylin-targeting weight loss medicine.",
    "url": "https://www.biopharmadive.com/news/alveus-obesity-biotech-startup-glp-gipr-amylin-financing/809148/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "c2d38228-b4ea-32a2-ab10-a7eab52db9ca",
      "content": {
        "id": "c2d38228-b4ea-32a2-ab10-a7eab52db9ca",
        "contentType": "STORY",
        "title": "Alveus launches with $160M to advance MariTide-like obesity drug",
        "description": "",
        "summary": "The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as well as an amylin-targeting weight loss medicine.",
        "pubDate": "2026-01-08T17:11:00Z",
        "displayTime": "2026-01-08T17:11:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/d37466ed4782563300403390b9007573",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aepGplpscgs.eEv5GHgx5Q--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/d37466ed4782563300403390b9007573.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yOyEGXE_i7I2OldkwNRWBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/d37466ed4782563300403390b9007573.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/alveus-obesity-biotech-startup-glp-gipr-amylin-financing/809148/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/alveus-launches-160m-advance-maritide-171100629.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]